49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details
臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01953835 (ClinicalTrials.gov) | October 4, 2013 | 26/9/2013 | A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184 | A Two-part Healthy Volunteer Study to Investigate Both the Interaction of GSK2586184 With Rosuvastatin and Simvastatin and to Compare the Pharmacokinetics of Two Different Formulations of GSK2586184 | Systemic Lupus Erythematosus | Drug: GSK2586184 standard formulation;Drug: Simvastatin;Drug: Rosuvastatin;Drug: GSK2586184 new formulation | GlaxoSmithKline | NULL | Completed | 18 Years | 65 Years | All | 37 | Phase 1 | United States |
| 2 | NCT01170585 (ClinicalTrials.gov) | July 2010 | 26/7/2010 | A Trial of Rosuvastatin in Systemic Lupus Erythematosus | A Randomised Placebo Controlled Trial of Rosuvastatin in Systemic Lupus Erythematosus | Atherosclerosis;Systemic Lupus Erythematosus | Drug: Rosuvastatin;Drug: Placebo | Imperial College London | NULL | Completed | 18 Years | 80 Years | Both | 33 | Phase 2 | United Kingdom |
| 3 | EUCTR2006-006214-16-GB (EUCTR) | 23/02/2010 | 29/02/2008 | A randomised placebo controlled trial of rosuvastatin in systemic lupus erythematosus. - RCT of statin in SLE | A randomised placebo controlled trial of rosuvastatin in systemic lupus erythematosus. - RCT of statin in SLE | Systemic lupus erythematosus. MedDRA version: 13.1;Level: LLT;Classification code 10042944;Term: Systemic lupus erythematosis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders | Trade Name: Crestor Product Name: Crestor INN or Proposed INN: ROSUVASTATIN CALCIUM Other descriptive name: rosuvastatin Trade Name: Crestor Product Name: Crestor INN or Proposed INN: ROSUVASTATIN CALCIUM Other descriptive name: rosuvastatin | Imperial College | NULL | Not Recruiting | Female: yes Male: yes | 64 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | United Kingdom | ||
| 4 | NCT00866229 (ClinicalTrials.gov) | April 2008 | 19/3/2009 | Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level | Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level | Systemic Lupus Erythematosus;High LDL Cholesterol Level | Drug: Rosuvastatin;Drug: Simvastatin | Ramathibodi Hospital | AstraZeneca | Recruiting | 18 Years | 60 Years | Both | 140 | Phase 4 | Thailand |
| 5 | NCT00371501 (ClinicalTrials.gov) | June 2006 | 1/9/2006 | Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus | Low Dose Aspirin and Statins for Primary Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus: A Randomized Double-blind Placebo-controlled Trial | Atherosclerosis;Thromboembolism;Systemic Lupus Erythematosus | Drug: Rosuvastatin;Drug: placebo;Drug: aspirin | Tuen Mun Hospital | AstraZeneca | Completed | 18 Years | N/A | Both | 72 | Phase 4 | Hong Kong |